We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · January 06, 2020

Obeticholic Acid for the Treatment of NASH

The Lancet


Additional Info

The Lancet
Obeticholic Acid for the Treatment of Non-Alcoholic Steatohepatitis: Interim Analysis From a Multicentre, Randomised, Placebo-Controlled Phase 3 Trial
Lancet 2019 Dec 14;394(10215)2184-2196, ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, P Bedossa, A Geier, S Beckebaum, PN Newsome, D Sheridan, MY Sheikh, J Trotter, W Knapple, E Lawitz, MF Abdelmalek, KV Kowdley, AJ Montano-Loza, J Boursier, P Mathurin, E Bugianesi, G Mazzella, A Olveira, H Cortez-Pinto, I Graupera, D Orr, LL Gluud, JF Dufour, D Shapiro, J Campagna, L Zaru, L MacConell, R Shringarpure, S Harrison, AJ Sanyal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading